BioDlink and Lepu Biopharma Join Forces to Release the First EGFR-Targeting ADC Drug BioDlink and Lepu Biopharma mark a significant milestone with the launch of MEIYOUHENG®, the first EGFR-targeting ADC drug, showcasing their collaborative achievement in biologics.

BioDlink and Lepu Biopharma Join Forces to Release the First EGFR-Targeting ADC Drug #China #Suzhou #BioDlink #Lepu_Biopharma #MEIYOUHENG